XML 97 R56.htm IDEA: XBRL DOCUMENT v3.25.0.1
Summary of significant accounting policies - Narrative (Details)
$ / shares in Units, $ in Millions
 12 Months Ended
Aug. 23, 2023
May 08, 2023
USD ($)
$ / shares
shares
Dec. 29, 2024
USD ($)
Segment
Employee
$ / shares
Dec. 31, 2023
USD ($)
$ / shares
Jan. 01, 2023
USD ($)
Jan. 02, 2022
USD ($)
Jan. 03, 2021
Dec. 29, 2019
Jul. 02, 2023
USD ($)
Concentration of Credit Risk [Line Items]                  
Number of employees | Employee     138,100            
Common Stock, Par or Stated Value Per Share | $ / shares     $ 1.00 $ 1.00          
Proceeds from Kenvue initial public offering     $ 0 $ 4,241 $ 0        
Realized gain (loss) on investment   $ 2,500              
Number of business segments | Segment     2            
Supplier finance program, obligation, current     $ 788 $ 704          
Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]     Accounts Payable, Current Accounts Payable, Current          
Minimum reverse repurchase agreement collateral (as a percent)     102.00%            
Accrued rebates, returns and promotions     $ 17,580 $ 16,001          
Sales return reserve (as a percent)     1.00% 1.00% 1.00%        
Percentage of profit share payments (less than)     2.00% 2.00% 3.00%        
Cost of products sold     $ 27,471 $ 26,553 $ 24,596        
Shipping and handling costs as a percent of sales     1.00% 1.00% 1.00%        
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]     Other assets, noncurrent Other assets, noncurrent          
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]     Accrued Liabilities, Current Accrued Liabilities, Current          
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]     Other Liabilities, Noncurrent Other Liabilities, Noncurrent          
Operating lease, right-of-use asset     $ 1,100 $ 1,000          
Operating lease liabilities     1,200 1,100          
Operating lease costs     200 200 $ 200        
Cash paid for operating leases     200 200 200        
Advertising expense     $ 600 $ 500 $ 700        
U.S. statutory rate     21.00% 21.00% 21.00%   21.00% 35.00%  
TCJA, undistributed foreign earnings percent related to cash and cash equivalents             15.50%    
TCJA, undistributed foreign earnings percent related to earnings other than cash and cash equivalents             8.00%    
TCJA, transition tax for accumulated foreign earnings, payment period     8 years            
TJCA , provisional liability, non-current     $ 2,500            
Repatriation of foreign earnings amount     500            
Selling, marketing and administrative expenses     $ 22,869 $ 21,512 $ 20,246        
Supplier finance program, payment timing, period     90 days            
Yellow Jersey Therapeutics                  
Concentration of Credit Risk [Line Items]                  
Payments to Acquire in Process Research and Development     $ 1,250            
Kenvue Inc.                  
Concentration of Credit Risk [Line Items]                  
Split-off percentage 80.10%                
Kenvue Inc.                  
Concentration of Credit Risk [Line Items]                  
Common Stock, Par or Stated Value Per Share | $ / shares   $ 0.01              
Sale of stock (in USD per share) | $ / shares   $ 22.00              
Johnson & Johnson | Kenvue Inc.                  
Concentration of Credit Risk [Line Items]                  
Percentage ownership after transaction   89.60%              
Common stock, value                 $ 1,300
Percentage ownership after transaction 9.50%                
IPO | Kenvue Inc.                  
Concentration of Credit Risk [Line Items]                  
Sale of stock, number of shares issued in transaction (in shares) | shares   198,734,444              
Proceeds from Kenvue initial public offering   $ 4,200              
Minimum                  
Concentration of Credit Risk [Line Items]                  
Revenue, performance obligation, payment terms     30 days            
Minimum | Software Development                  
Concentration of Credit Risk [Line Items]                  
Estimated useful lives of the assets     3 years            
Maximum                  
Concentration of Credit Risk [Line Items]                  
Revenue, performance obligation, payment terms     90 days            
Maximum | Software Development                  
Concentration of Credit Risk [Line Items]                  
Estimated useful lives of the assets     8 years            
R&D Expense | Project Concentration Risk                  
Concentration of Credit Risk [Line Items]                  
Concentration risk, threshold percentage (as a percent)     0.05 0.05 0.05        
Shipping and Handling                  
Concentration of Credit Risk [Line Items]                  
Selling, marketing and administrative expenses     $ 900 $ 900   $ 800      
Pharmaceutical                  
Concentration of Credit Risk [Line Items]                  
Accrued rebates, returns and promotions     $ 12,300 $ 11,500